Indian health authorities are reportedly keen of making breakthrough in the field of research for HIV/AIDS, though the assessment of vaccine for HIV/AIDS is still lingering in perched animation because of the fluctuation of vaccine in terms of mass fabrication.

Tested jointly at National AIDS Research Institute (NARI), Pune, and the Tuberculosis Research Centre here, the vaccine, which is said to be a “Modified Vaccinia” and is developed out of Indian HIV sprain, was tested as part of a joint venture by the Tuberculosis Research Centre (TRC) and NARI, the National AIDS Research Institute, Pune.

The foremost rationale behind the deadlock is the verity that the “Modified Vaccinia” actually resolved into an acute and ‘unstable' vaccine candidate, despite ample attempts made for scaling up the same.

Expressing his dilemma regarding the vaccine, principal investigator at the National Institute for Research in Tuberculosis (NIRT), V. D Ramanathan said that the biggest issue is that the intended vaccine is utterly multifarious.

It was revealed that almost six out of nine HIV genes (related to the Indian sprain) that have intentionally been tailored (for ensuring minimum damage), are fused with a vaccine meant for smallpox.

He stressed that the creation is full of hopes, but the technology desperately needed to enhance and sustain the vaccine are still not there. Still, efforts and hopes are on, he said.